An open-label, randomized, comparative study investigating efficacy and safety of iron supplement vs. ferrous ascorbate tablet in pregnant women with iron deficiency anemia. - NIL

Start Date20 Jul 2024

Sponsor / Collaborator

Generex Pharmassist Pvt Ltd.

100 Clinical Results associated with Ferrous Sulfate/Ascorbic Acid

100 Translational Medicine associated with Ferrous Sulfate/Ascorbic Acid

100 Patents (Medical) associated with Ferrous Sulfate/Ascorbic Acid

11,677

Literatures (Medical) associated with Ferrous Sulfate/Ascorbic Acid

01 Feb 2025·Talanta

Do probiotics and iron supplementation have any impact on element distribution in rat kidneys? – bioimaging by laser ablation inductively coupled plasma mass spectrometry

Article

Author: Hanć, Anetta ; Sajnóg, Adam ; Skrypnik, Katarzyna ; Frąckowiak, Julia ; Komorowicz, Izabela ; Suliburska, Joanna

This study investigates the influence of multistrain probiotics and iron supplementation on the distribution and interaction of trace elements in the kidneys of Wistar rats using laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS) bioimaging. Forty 6-week-old female Wistar rats were divided into five groups, each fed an AIN-93 M diet with varying additions or deficiencies of iron and probiotics, which included a control, an iron-deficient diet, an iron-deficient diet with probiotics, an iron-deficient diet with iron supplementation, and an iron-deficient diet with both probiotics and iron supplementation. The obtained two-dimensional maps of the distribution of elements reveal distinct locations of Cu, Fe, Mn, and Zn in specific tissues of rat kidneys. Specifically, Cu and Fe were co-localized in the renal cortex, while Zn was mostly absent from regions where Cu and Fe accumulated. Fe supplementation alone increased Fe in the renal cortex, while probiotics enhanced this effect, suggesting a synergistic role in Fe absorption. The total content of elements in the kidneys of all groups was determined after digestion: Cu 13.3-24.7 mg kg^-¹, Fe 218-509 mg kg^-¹, Mn 0.87-1.29 mg kg^-¹, and Zn 28.6-40.1 mg kg^-¹. Competitive interactions among Cu, Fe, and Zn were observed, with probiotics modulating their concentrations and distribution, highlighting their role in trace element homeostasis. Our research provides insights into the interactions between dietary supplements, probiotics, and trace element distribution in kidneys, paving the way for targeted nutritional interventions. This study highlights the need for further research on trace element functions in organisms and their impact on health.

01 Feb 2025·European Journal of Nutrition

Is underweight associated with poorer diet, nutrient status, bone and cardiometabolic health, and school performance in Danish 8-11-year-olds?

Article

Author: Strandberg-Larsen, Katrine ; Damsgaard, Camilla T ; Aurup, Anne V. ; Andersen, Rikke ; Damsgaard, Camilla T. ; Aurup, Anne V ; Lauritzen, Lotte ; Biltoft-Jensen, Anja

AbstractPurposeUnderweight, i.e. low body mass index for age and sex, may indicate undernutrition, but despite high prevalence, this aspect is largely overlooked in children in high-income countries. We explored if dietary intake, nutrient status, body composition, bone mineralization, cardiometabolic markers and school performance differed in schoolchildren with underweight compared to normal- and overweight.MethodsWe used cross-sectional data from 815 Danish 8-11-year-old children collected in 2011. Intake of foods, macronutrients and key micronutrients (vitamin D, vitamin B12, calcium, iron, zinc and selenium) was assessed by 7-day dietary records. Measurements included anthropometry, dual-energy X-ray absorptiometry and tests of attention and reading skills. Fasting blood samples were analyzed for biomarkers of iron, long-chain n-3 fatty acids and vitamin D status as well as blood lipids, insulin and growth markers.ResultsEighty-three (10.2%) children had underweight and were shown to have a lower intake of energy, red meat, protein and zinc and higher intake of added sugar than children with normal- and overweight. They also had higher fish intake relative to overweight, but blood biomarkers did not differ between groups. Children with underweight had lower fat percent and bone mineralization compared to peers with normalweight, but apart from lower insulin, they did not differ in overall cardiometabolic health or school performance.ConclusionAlthough we found some differences in diet, there were no considerable differences in nutrient status, cardiometabolic health or school performance between children with underweight and their normalweight peers. However, the lower bone mineralization is a concern and needs further investigation.

01 Jan 2025·The Journal of Pediatrics

Supplemental Iron and Recombinant Erythropoietin for Anemia in Infants Born Very Preterm: A Survey of Clinical Practice in Europe

Article

Author: Reibel-Georgi, Nora J. ; Soares, Henrique ; Matasova, Katarina ; Brække, Kristin ; Stanworth, Simon J ; Reibel-Georgi, Nora J ; Cools, Filip ; Szabó, Miklós ; Ghirardello, Stefano ; Carrascosa, Marta Aguar ; Szczapa, Tomasz ; New, Helen V. ; Krivec, Jana Lozar ; Heeger, Lisanne E. ; New, Helen V ; Sankilampi, Ulla ; Farrugia, Ryan ; Heeger, Lisanne E ; Lopriore, Enrico ; Dame, Christof ; Zaharie, Gabriela ; Scrivens, Alexandra ; Stanworth, Simon J. ; Muehlbacher, Tobias ; Cardona, Francesco ; Deschmann, Emöke ; Roehr, Charles Christoph ; Fustolo-Gunnink, Suzanne

OBJECTIVESTo survey practices of iron and recombinant human erythropoietin (rhEpo) administration to infants born preterm across Europe.STUDY DESIGNOver a 3-month period, we conducted an online survey in 597 neonatal intensive care units (NICUs) of 18 European countries treating infants born with a gestational age of <32 weeks.RESULTSWe included 343 NICUs (response rate 56.3%) in the survey. Almost all NICUs (97.7%) routinely supplement enteral iron, and 74.3% of respondents to all infants born <32 weeks of gestation. We found that 65.3% of NICUs routinely evaluate erythropoiesis and iron parameters beyond day 28 after birth. Most NICUs initiate iron supplementation at postnatal age of 2 weeks and stop after 6 months (34.3%) or 12 months (34.3%). Routine use of rhEpo was reported in 22.2% of NICUs, and in individual cases in 6.9%. RhEpo was mostly administered subcutaneously (70.1%) and most frequently at a dose of 250 U/kg 3 times a week (44.3%), but the dose varied greatly between centers.CONCLUSIONSThis survey highlights wide heterogeneity in evaluating erythropoietic activity and iron deficiency in infants born preterm. Variation in iron supplementation during infancy likely reflects an inadequate evidence base. Current evidence on the efficacy and safety profile of rhEpo is only poorly translated into clinical practice. This survey demonstrates a need for standards to optimize patient blood management in anemia of prematurity.

News (Medical) associated with Ferrous Sulfate/Ascorbic Acid

01 Dec 2023

·www.sciencedaily.com

Meteorites likely source of nitrogen for early Earth

Micrometeorites originating from icy celestial bodies in the outer Solar System may be responsible for transporting nitrogen to the near-Earth region in the early days of our solar system. Micrometeorites originating from icy celestial bodies in the outer Solar System may be responsible for transporting nitrogen to the near-Earth region in the early days of our solar system. That discovery was published today in Nature Astronomy by an international team of researchers, including University of Hawai'i at Manoa scientists, led by Kyoto University. Nitrogen compounds, such as ammonium salts, are abundant in material born in regions far from the sun, but evidence of their transport to Earth's orbital region had been poorly understood. "Our recent findings suggests the possibility that a greater amount of nitrogen compounds than previously recognized was transported near Earth, potentially serving as building blocks for life on our planet," says Hope Ishii, study co-author and affiliate faculty at the Hawai'i Institute of Geophysics and Planetology in the UH Manoa School of Ocean and Earth Science and Technology (SOEST). Like all asteroids, Ryugu is a small, rocky object that orbits the sun. The Japan Aerospace Exploration Agency's Hayabusa2 spacecraft explored Ryugu and brought material from its surface back to Earth in 2020. This intriguing asteroid is rich in carbon and has undergone significant space weathering caused by micrometeorite collisions and exposure to charged ions streaming from the sun. In this study, the scientists aimed to discover clues about the materials arriving near Earth's orbit, where Ryugu is currently located, by examining the evidence of space weathering in Ryugu samples. Using an electron microscope, they found that the surface of the Ryugu samples are covered with tiny minerals composed of iron and nitrogen (iron nitride: Fe4N). "We proposed that tiny meteorites, called micrometeorites, containing ammonia compounds were delivered from icy celestial bodies and collided with Ryugu," said Toru Matsumoto, lead author of the study and assistant professor at Kyoto University. "The micrometeorite collisions trigger chemical reactions on magnetite and lead to the formation of the iron nitride." The iron nitride was observed on the surface of magnetite, which consists of iron and oxygen atoms. When magnetite is exposed to the space environment, oxygen atoms are lost from the surface by the irradiation of hydrogen ions from the sun (solar wind) and by heating through micrometeorite impact. These processes form metallic iron on the very surface of the magnetite, which readily reacts with ammonia, creating ideal conditions for synthesis of iron nitride.

16 Nov 2023

·www.globenewswire.com

Alterity Therapeutics Announces Presentation of New Data Demonstrating Novel Mechanisms of ATH434

MELBOURNE, Australia and SAN FRANCISCO, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced promising new data related to ATH434 was presented at the Society for Neuroscience that took place November 11-15, 2023, in Washington, D.C. The poster entitled, “Potent Antioxidant and Mitochondrial-protectant Effects of ATH434, a Novel Inhibitor of α-Synuclein Aggregation with Moderate Iron-binding Affinity,” presents new data indicating that ATH434 can preserve mitochondrial function after oxidative injury and exert direct anti-oxidant activity independent of its iron binding properties. These features were not observed with another iron binding agent approved for treating iron overload that was also investigated. The study was run under the direction of Dr. Daniel J. Kosman, Distinguished Professor of Biochemistry at the State University of New York at Buffalo. David Stamler, M.D., Chief Executive Officer of Alterity, commented, “These exciting new data underscore the potential of ATH434 as a treatment for neurodegenerative diseases, including Parkinson’s disease and related disorders. We have long known that ATH434 is able to reduce labile iron which, when elevated, can drive oxidative stress. The demonstrated mitochondrial protection may reveal additional mechanisms that augment its ability to slow disease progression. We are grateful for the valued contributions from our collaborators in Dr. Kosman’s laboratory at SUNY-Buffalo.” The study, authored by Dr. Danielle Bailey, investigated the efficacy of ATH434 and comparator agents as mitochondrial protectants using a menadione-induced model of oxidative stress in a neuronal cell line. A suite of in-solution assays detailed the mechanisms underlying ATH434’s direct antioxidant capacity. The poster presentation can be accessed on Alterity’s website under The Science page. About ATH434 Alterity’s lead candidate, ATH434, is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. ATH434 has been shown preclinically to reduce α-synuclein pathology and preserve neuronal function by restoring normal iron balance in the brain. As an iron chaperone, it has excellent potential to treat Parkinson’s disease as well as various Parkinsonian disorders such as Multiple System Atrophy (MSA). ATH434 successfully completed Phase 1 studies demonstrating the agent is well tolerated and achieved brain levels comparable to efficacious levels in animal models of MSA. ATH434 is currently being studied in two clinical trials: Study ATH434-201 is a randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with early-stage MSA and Study ATH434-202 is an open-label Phase 2 Biomarker trial in patients with more advanced MSA. ATH434 has been granted Orphan drug designation for the treatment of MSA by the U.S. FDA and the European Commission. About Alterity Therapeutics Limited Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has the potential to treat various Parkinsonian disorders and is currently being evaluated in two Phase 2 clinical trials in Multiple System Atrophy. Alterity also has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s web site at www.alteritytherapeutics.com. Authorisation & Additional informationThis announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited. Investor and Media Contacts: AustraliaHannah Howlettwe-aualteritytherapeutics@we-worldwide.com+61 450 648 064 U.S.Remy Bernardaremy.bernarda@iradvisory.com +1 (415) 203-6386 Forward Looking Statements This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company’s patent rights and the uncertainty of the Company freedom to operate. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Clinical ResultPhase 2Phase 1Orphan Drug

25 Oct 2023

·www.prnewswire.com

Renibus Announces First Patient Enrolled in PROTECT Phase 3 Study of RBT-1 to Reduce Post-operative Complications After Cardiothoracic Surgery

Pivotal trial will evaluate the effect of RBT-1 as a preconditioning agent in people undergoing cardiothoracic surgeryEstimated 600K CABG and valve repair surgeries in US/year, creating a large initial market for RBT-1PROTECT enrollment on track, NDA filing anticipated early 2026 SOUTHLAKE, Texas, Oct. 25, 2023 /PRNewswire/ -- Renibus Therapeutics® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardio-renal and metabolic diseases, today announced that the first patient has been dosed in the pivotal Phase 3 PROTECT trial of RBT-1, the Company's first-in-a-new-class preconditioning agent under investigation to reduce post-operative complications following cardiothoracic surgery. PROTECT is expected to be conducted at approximately 35 sites in the United States and Canada. Continue Reading Post-operative complications from cardiothoracic surgery represent a major unmet medical need. In the United States (US), there are approximately 600,000 CABG, valve repair, and related procedures conducted annually, with 66% of patients having complications that result in $6.5 billion in unnecessary healthcare costs. This represents a significant and growing initial market for RBT-1, which if approved, would be the first and only approved pharmacological therapy to reduce the risk of post operative complications following cardiothoracic surgery. RBT-1 (stannic protoporfin/iron sucrose), a fixed dose combination product given once intravenously over 1-2 hours, 24-48 hours before surgery, is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways. In a completed Phase 2 study, RBT-1 demonstrated statistically significant positive data in primary and several secondary endpoints, with reduced time in the ICU, shortened patient recovery time and fewer hospital readmissions. "We are pleased to initiate our PROTECT Phase 3 study of RBT-1. This milestone represents a significant step towards addressing the unmet needs associated with post-operative complications after cardiothoracic surgery, and underscores our commitment to transforming this treatment landscape," said Frank Stonebanks, Co-CEO of Renibus. "With our pivotal trial now underway in our PROTECT program, we are considering ways to expand the opportunity with RBT-1 across a wide spectrum of procedures and post-operative complications, including potentially transplant surgeries, TAVR's (trans aortic valve replacements) and thoracic aortic aneurysms. We believe that RBT-1 has broad "pipeline-in-a-product" potential, and we look forward to executing well in Phase 3 and bringing our product to patients in need." PROTECT is a Phase 3, Rand omized, Double-Blind, Placebo-Controlled S tudy to Evaluate the Effect of RBT-1 on Reducing the Risk of Post-Operative Complica tions in Subjects Undergoing Cardiac Surgery. The study is a randomized, double-blind, multi-center, placebo-controlled trial evaluating the effect of RBT-1 in approximately 400 patients. The primary endpoint is a severity-based composite hierarchy using the Win-Ratio or Finkelstein-Schoenfeld Method that includes the following: death, AKI requiring dialysis, ICU days, and 30-day cardiopulmonary readmission rates. Secondary and exploratory objectives include time on the ventilator, need for blood products, new onset atrial fibrillation, delirium, hospital length of stay, cost effective analyses and safety. Top line results are expected mid-2025. Charles A. Mack, MD, FACS, Associate Professor of Cardiothoracic Surgery, New York-Presbyterian Hospital, Weill Cornell Medicine, added, "The cardiac surgery community is grateful for Renibus' commitment to bringing a new treatment option forward for patients undergoing cardiac surgery. RBT-1 is a potentially transformational pre-conditioning product, and I am enthusiastic about the initial results demonstrated in our patients." About RBT-1 RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways currently in Phase 3 [NCT # 06021457] for its lead indication to reduce post-operative complications following cardiothoracic surgery. Renibus completed the Phase 2 study of RBT-1 (NCT04564833) in February 2023 and announced positive final results from this study in May 2023. In October 2023, Renibus initiated enrollment and administration of RBT-1 in its PROTECT Phase 3 pivotal study. RBT-1 was granted Breakthrough Therapy designation status from the U.S. FDA to reduce the risk of complications in patients undergoing cardiothoracic surgery. About Renibus Therapeutics Renibus is a clinical stage biopharmaceutical company dedicated to treating, improving and extending patients' lives by developing products to prevent disease progression, improve outcomes and protect against organ damage associated with cardiorenal and metabolic diseases. Renibus' first-in-class lead program is RBT-1, currently being evaluated in a pivotal Phase 3 PROTECT study. RBT-3 is a novel, low molecular weight iron nanoparticle that has the potential to rapidly resolve iron deficiency and may reduce the risk of cisplatin-induced nephrotoxicity. RBT-9 (stannic protoporfin) is a potent anti-inflammatory and antioxidant drug with broad spectrum anti-viral properties. It has been investigated in a 42-patient Phase 2, randomized, placebo-controlled trial in high-risk patients with COVID-19. The data from this trial indicated the RBT-9 has the potential to significantly improve clinical outcomes in life threatening viral infections. Additional pre-clinical work is underway to help inform the clinical development strategy. For more information, please visit the Company's website at and engage with us on LinkedIn. Investor and Media Contact: Amy Conrad Juniper Point [email protected] 858-914-1962 Business Development Contact Frank Stonebanks Co-CEO, Renibus [email protected] SOURCE Renibus Therapeutics

Phase 2Phase 3Breakthrough Therapy

100 Deals associated with Ferrous Sulfate/Ascorbic Acid

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB13257

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anemia, Iron-Deficiency	CN	-	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EHA2022	Not Applicable	COVID-19	60	Sucrosomial® iron	qxpekmbbfk(jhldppwcya) = uxgmimhryw qgtxfmverb (swisiscrai ) View more	-	10 Jun 2022
				iron oral formulation (No iron support)	qxpekmbbfk(jhldppwcya) = ckdmmpfchx qgtxfmverb (swisiscrai ) View more
EHA2019	Not Applicable	-	36	Iron Sulphate	xygplpwyvf(yfxjseojoz) = rqxldthpph qxclusiydy (qhtsecgwci )	-	16 May 2019
				Sucrosomial® Iron	xygplpwyvf(yfxjseojoz) = qoonffbati qxclusiydy (qhtsecgwci )
EHA2019	Not Applicable	Myelodysplastic Syndromes	45	Group A (sodium ferrigluconate)	qwmplkdedk(pebcpwafbr) = jmmnvbmqtv qvnxhwqjto (clbsitphaq ) View more	-	16 May 2019
				Group B (sucrosomial iron)	qwmplkdedk(pebcpwafbr) = erhemmravw qvnxhwqjto (clbsitphaq ) View more
ASN2018	Not Applicable	Hodgkin's Lymphoma MDA-LDL \| NTBI \| TSAT ... View more	-	Oral ferrous sulfate 105mg	zxcsdmqkdl(drmwqdzvdm) = rhfvwudoij ttlnemghps (hzxlqtaeiw, 104 - 320) View more	Positive	23 Oct 2018
				Oral Iron Administration (OIA)	pwxnbkuyts(oogzlwrspb) = utibvpykrd izdlxhkleb (xfomwbfegr, 68 - 124)
EHA2015	Not Applicable	Myelodysplastic Syndromes	107	ERYTHROPOIETIN (No support)	(wvjxtucaxz) = acywselhdo pkouqpwzud (oqeoxszfgz ) View more	-	21 May 2015
				Epo support	(wvjxtucaxz) = tegvfghtyq pkouqpwzud (oqeoxszfgz ) View more
DOPPS (ASN2012)	Not Applicable	TSAT \| ferritin \| hemoglobin	-	IV Iron Dose	(dykksxunmq) = ndqrtjhbhr wbhncnadlo (zxghwkezuj ) View more	Negative	30 Oct 2012
				IV Iron	(dykksxunmq) = yozfoigzom wbhncnadlo (zxghwkezuj ) View more
ASN2010	Not Applicable	Chronic Kidney Diseases	112	IV Iron	etsgpxqhix(yxedrnxcvg) = After IVfe, there were significant ↑ ’s in %fe osnsyxkncx (osxliqcmlu ) View more	Positive	16 Nov 2010

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis